[用胞磷胆碱（喜复康）对缺血性中风患者进行神经保护治疗]

[Neuroprotective treatment with citicoline (ceraxon) in patients with ischemic stroke].

作者信息

Martynov M Iu, Boĭko A N, Kamchatnov P R, Kabanov A A, Iasamanova A N, Shchukin I A, Kolesnikova T I, Chubykin V I, Glukhareva A P, Gusev E I

出版信息

Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(3 Pt 2):21-6.

PMID:22677765

Abstract

The dynamics of neurological symptoms assessed with the Scandinavian stroke scale, the Barthel index and the modified Rankin scale was studied in 89 patients with moderate ischemic stroke who received citicoline (ceraxone) intravenously and orally. The results were compared to a group of 52 age-, sex- and stroke-matched patients who did not receive citicoline. To the date of discharge from the hospital (days 21-24), the full restoration (p<0.05) was noted in patients of the main group. Efficacy of citicoline was significantly (p<0.05) higher in patients younger than 70 years and when the drug was used in the first hours of disease.

摘要

对89例中度缺血性卒中患者进行了研究，这些患者静脉内和口服使用了胞磷胆碱（西吡氯铵），并用斯堪的纳维亚卒中量表、巴氏指数和改良Rankin量表评估神经症状的动态变化。将结果与52例年龄、性别和卒中情况相匹配但未接受胞磷胆碱治疗的患者组进行比较。到出院日期（第21 - 24天），主要组患者出现完全恢复（p<0.05）。在70岁以下患者以及在疾病最初几小时使用该药物时，胞磷胆碱的疗效显著更高（p<0.05）。